medigraphic.com
Órgano oficial de la Sociedad Mexicana de Cirugía Dermatológica y Oncológica, AC

2022, Número 4

<< Anterior Siguiente >>

Dermatología Cosmética, Médica y Quirúrgica 2022; 20 (4)


Viruela símica, revisión de la literatura: antecedentes históricos, epidemiología, formas de contagio, cuadro clínico, síntomas, mortalidad y grupos vulnerables, tratamiento y vacunación

Romo LA, Arteaga PR, Vega MME, Fonte ÁV

Idioma: Español
Referencias bibliográficas: 39
Paginas: 459-467
Archivo PDF: 251.88 Kb.


RESUMEN

A 52 años de la descripción del primer caso de viruela símica en humanos, aún estamos aprendiendo sobre su comportamiento. Realizamos una revisión de la literatura desde los antecedentes históricos, la epidemiología y el cuadro clínico. Además, incorporamos datos sobre grupos vulnerables a la enfermedad y las recomendaciones actuales para el manejo de los pacientes.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Ladnyi ID, Ziegler P y Kima A, A human infection caused by monkeypoxvirus in Basankusu territory, Democratic Republic of the Congo,Bull World Health Organ 1972; 46:593-97.

  2. Heymann DL, Szczeniowski M y Esteves K, Re-emergence of monkeypoxin Africa: a review of the past six years, Br Med Bull 1998;54(3):693-702. Disponible en: https://doi.org/10.1093/oxfordjournals.bmb.a011720.

  3. Breman JG, Kalisa-Ruti, Steniowski MV, Zanotto E, Gromyko AI yArita I, Human monkeypox, 1970-79, Bull World Health Organ 1980;58(2):165-82.

  4. Bayer-Garner IB, Monkeypox virus: histologic, immunohistochemicaland electron-microscopic findings, J Cutan Pathol 2005; 32(1):28-34.Disponible en: https://pubmed.ncbi.nlm.nih.gov/15660652/.

  5. Khodakevich L, Jezek Z y Kinzanzka K, Isolation of monkeypox virusfrom wild squirrel infected in nature, Lancet 1986; 327(8472):98-9. Disponibleen: https://pubmed.ncbi.nlm.nih.gov/2867342/.

  6. Ladnyj ID, Ziegler P y Kima E, A human infection caused by monkeypoxvirus in Basankusu territory, Democratic Republic of the Congo,Bull World Health Organ Bull 1972; 46(5):593-7. Disponible en: https://pubmed.ncbi.nlm.nih.gov/4340218/.

  7. Bryer J, Freeman EE y Rosenbach M, Monkeypox emerges on a globalscale: a historical review and dermatologic primer, J Am Acad Dermatol2022. Disponible en: https://pubmed.ncbi.nlm.nih.gov/35817333/.

  8. Yinka-Ogunleye A, Aruna O, Dalhat M, Ogoina D, McCollum A, DisuY et al., Outbreak of human monkeypox in Nigeria in 2017-18: a clinicaland epidemiological report, Lancet Infect Dis 2019; 19(8):872.9. Disponibleen: https://pubmed.ncbi.nlm.nih.gov/31285143/.

  9. paho, Informe semanal de situación sobre la respuesta al brote deviruela símica en varios países: región de las Américas. Disponibleen: https://iris.paho.org/bitstream/handle/10665.2/56302/InfoSit_ViruelaSimica_12ago.pdf?sequence=1&isAllowed=y.

  10. Centers for Disease Control and Prevention (cdc), Monkeypox outbreakglobal map, 2022. Disponible en: https://www.cdc.gov/poxvirus/monkeypox/response/2022/world-map.html.

  11. World Health Organization (who), Emergency response. Clinicalmanagement and infection prevention and control for monkeypox:interim rapid response guidance, 10 June 2022. Disponible en:https://www.who.int/publications/i/item/WHO-MPX-Clinical-and-IPC-2022.1.

  12. Catalá A, Clavo-Escribano P, Riera-Monroig J, Martín-Ezquerra G,Fernández-González P, Revelles-Peñas L et al., Monkeypox outbreakin Spain: clinical and epidemiological findings in a prospective crosssectionalstudy of 185 cases, Br J Dermatol 2022. Disponible en: https://pubmed.ncbi.nlm.nih.gov/35917191/.

  13. Patel A, Bilinska J, Tam JC, Da Silva Fontoura D, Mason CY, Daunt Aet al., Clinical features and novel presentations of human monkeypoxin a central London centre during the 2022 outbreak: descriptive caseseries, bmj 2022; 378:e072410. Disponible en: https://www.bmj.com/content/378/bmj-2022-072410.long.

  14. Reed KD, Melski JW, Graham MB, Regnery RL, Sotir MJ, WegnerMV et al., The detection of monkeypox in humans in the WesternHemisphere, N Engl J Med 2004; 350(4):342-50. Disponible en: http://dx.doi.org/10.1056/NEJMoa032299.

  15. paho, Actualización epidemiológica viruela símica en niños, adolescentesy mujeres embarazadas, 4 de agosto de 2022. Disponible en:https://www.paho.org/es/documentos/actualizacion-epidemiologica-viruela-simica-ninos-adolescentes-mujeres-embarazadas-4.

  16. Mbala PK, Huggins JW, Riu-Rovira T, Ahuka SM, Mulembakani P,Rimoin AW et al., Maternal and fetal outcomes among pregnantwomen with human monkeypox infection in the Democratic Republicof Congo, J Infect Dis 2017; 216(7):824-8. Disponible en: https://pubmed.ncbi.nlm.nih.gov/29029147/.

  17. Ogoina D, Iroezindu M, James HI, Oladokun R, Yinka-Ogunleye A,Wakama P et al., Clinical course and outcome of human monkeypoxin Nigeria, Clin Infect Dis 2020; 71(8):e210-4. Disponible en: https://pubmed.ncbi.nlm.nih.gov/32052029/.

  18. Ferringer T, Ko C, Peckham SM, DiCaudo DJ y Elston DM, Monkeypox,Dermatopathology, Londres, W. B. Saunders; 2008.

  19. Damon IK, Status of human monkeypox: clinical disease, epidemiologyand research, Vaccine 2011; 29 Suppl 4:D54-9. Disponible en: http://dx.doi.org/10.1016/j.vaccine.2011.04.014.

  20. Reynolds M, McCollum A, Nguete B, Shongo Lushima R y PetersenB, Improving the care and treatment of monkeypox patients in lowresourcesettings: applying evidence from contemporary biomedicaland smallpox biodefense research, Viruses 2017; 9(12):380. Disponibleen: http://dx.doi.org/10.3390/v9120380.

  21. Grosenbach DW, Honeychurch K, Rose EA, Chinsangaram J, Frimm A,Maiti B et al., Oral tecovirimat for the treatment of smallpox, N EnglJ Med 2018; 379(1):44-53. Disponible en: http://dx.doi.org/10.1056/nejmoa1705688.

  22. Adler H, Gould S, Hine P, Snell LB, Wong W, Houlihan CF et al., Clinicalfeatures and management of human monkeypox: a retrospectiveobservational study in the UK, Lancet Infect Dis 2022; 22(8):1153-62.Disponible en: http://dx.doi.org/10.1016/s1473-3099(22)00228-6.

  23. World Health Organization, Vaccines and immunization for monkeypoxinterim guidance 14 June 2022, who, 2022.

  24. Rizk JG, Lippi G, Henry BM, Forthal DN y Rizk Y, Prevention and treatmentof monkeypox, Drugs 2022; 82(9):957-63. Disponible en: http://dx.doi.org/10.1007/s40265-022-01742-y.

  25. Food and Drug Administration (fda), jynneos, 2022. Disponible en:https://www.fda.gov/vaccines-blood-biologics/jynneos.

  26. Centers for Disease Control and Prevention (cdc), jynneos vaccine,2022. Disponible en: https://www.cdc.gov/poxvirus/monkeypox/interim-considerations/jynneos-vaccine.html.

  27. Centers for Disease Control and Prevention (cdc), acam2000 vaccine,2022. Disponible en: https://www.cdc.gov/poxvirus/monkeypox/interim-considerations/acam2000-vaccine.html.

  28. Rao AK, Petersen BW, Whitehill F, Razeq JH, Isaacs SN, MerchlinskyMJ et al., Use of jynneos (smallpox and monkeypox vaccine, live,nonreplicating) for preexposure vaccination of persons at risk foroccupational exposure to orthopoxviruses: recommendations of theAdvisory Committee on Immunization Practices, United States, 2022,Morb Mortal Wkly Rep 2022; 71(22):734-42. Disponible en: http://dx.doi.org/10.15585/mmwr.mm7122e1.

  29. Nafziger SD, Smallpox, Crit Care Clin 2005; 21(4):739-46. Disponible en:https://www.who.int/health-topics/smallpox.

  30. Aguirre-Bolaños N, La etapa posterior a la erradicación de la viruela enMéxico, 1952-1977, História, Ciências, Saúde-Manguinhos 2018, 25(3):871-7.Disponible en: .

  31. epa, Disinfectants for emerging viral pathogens (evps): List q. 2022”.Disponible en: https://www.epa.gov/pesticide-registration/disinfectants-emerging-viral-pathogens-evps-list-q.

  32. Centers for Disease Control and Prevention (cdc), Isolation and infectioncontrol at home, 2022. Disponible en: http://ttps://www.cdc.gov/poxvirus/monkeypox/specific-settings/home-disinfection.html.

  33. Centers for Disease Control and Prevention (cdc), Isolation andprevention practices for people with monkeypox, 2022. Disponibleen: https://www.cdc.gov/poxvirus/monkeypox/clinicians/isolationprocedures.html.

  34. Centers for Disease Control and Prevention (cdc), Pets in the home,2022. Disponible en: https://www.cdc.gov/poxvirus/monkeypox/specific-settings/pets-in-homes.html.

  35. Antinori A, Mazzotta V, Vita S et al., Epidemiological, clinical and virologicalcharacteristics of four cases of monkeypox support transmissionthrough sexual contact, Italy, May 2022, Euro Surveill 2022;27(22):2200421. doi:10.2807/1560-7917.ES.2022.27.22.2200421.

  36. Thornhill JP, Barkati S, Walmsley S et al., Monkeypox virus infectionin humans across 16 countries, April-June 2022, N Engl J Med 2022;387(8):679-91. doi: 10.1056/NEJMoa2207323.

  37. Centers for Disease Control and Prevention (cdc), Safer sex, socialgatherings, and monkeypox, 2022. Disponible en: https://www.cdc.gov/poxvirus/monkeypox/prevention/sexual-health.html.

  38. Pittman PR, Martin JW, Kingebeni PM, Tamfum JM, Wan Q, ReynoldsMG et al., Clinical characterization of human monkeypox infectionsin the Democratic Republic of the Congo, bioRxiv 2022. Disponibleen: https://www.medrxiv.org/content/10.1101/2022.05.26.22273379v1.full.pdf.

  39. Grant R, Nguyen BL y Breban R, Modelling human-to-human transmissionof monkeypox, Bull World Health Organ 2020; 98(9):638-40.Disponible en: http://dx.doi.org/10.2471/BLT.19.242347.




2020     |     www.medigraphic.com